Metabolic dysfunction-associated fatty liver disease: a year in review

Current Opinion in Gastroenterology, Journal Year: 2022, Volume and Issue: 38(3), P. 251 - 260

Published: Feb. 9, 2022

Purpose of review In 2020, a novel comprehensive redefinition fatty liver disease was proposed by an international panel experts. This aims to explore current evidence regarding the impact this new definition on understanding epidemiology, pathogenesis, diagnosis, and clinical trials for disease. Recent findings The effectiveness metabolic dysfunction-associated (MAFLD) compared existing criteria nonalcoholic (NAFLD). data robustly suggest superior utility MAFLD in identifying patients at high risk dysfunction, hepatic extra-hepatic complications, as well those who would benefit from genetic testing, including with concomitant diseases. change name also appears have improved awareness among physicians. Summary transformation NAFLD represents important milestone, which indicates significant tangible progress towards more inclusive, equitable, patient-centred approach addressing profound challenges Growing has illustrated broader specific contexts that tremendous potential positively influencing diagnosis treatment. addition, momentum accompanying included widespread public attention unique burden previously underappreciated

Language: Английский

---

NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations

Journal of Clinical Medicine, Journal Year: 2021, Volume and Issue: 10(3), P. 467 - 467

Published: Jan. 26, 2021

Overwhelming evidence suggests an association of cardiovascular disease (CVD) with non-alcoholic fatty liver (NAFLD); however, the underlying mechanisms remain largely speculative. It is, likely that common contribute to development CVD and NAFLD, lifestyle factors such as smoking, sedentary poor nutrition habits physical inactivity being major candidates. These behavioral factors, on a predisposing genetic background, trigger changes in gut microbiota, inflammation, dyslipidemia oxidative stress, leading metabolic syndrome, diabetes obesity well atherosclerosis. Treatment options counteract both progression NAFLD include interventions, optimal medical therapy comorbid conditions and, final possibility, bariatric surgery. As no causal pharmacotherapy is available, further research urgently needed address unmet need growing population CVD.

Language: Английский

---

Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists

Journal of Hepatology, Journal Year: 2021, Volume and Issue: 74(5), P. 1254 - 1256

Published: Feb. 11, 2021

Language: Английский

---

Nonalcoholic fatty liver disease or metabolic dysfunction‐associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches

European Journal of Clinical Investigation, Journal Year: 2021, Volume and Issue: 51(7)

Published: Feb. 14, 2021

A consensus of experts has proposed to replace the term nonalcoholic fatty liver disease (NAFLD), whose global prevalence is 25%, with metabolic dysfunction-associated (MAFLD), describe more appropriately related derangements. MAFLD closely intertwined type 2 diabetes, obesity, dyslipidaemia, all linked a rise in risk cardiovascular (CVDs). Since controversy still stands on whether or not NAFLD/MAFLD raises odds CVD, present review aims evaluate impact aetiologies CV health and potential correction by dietary drug approaches.Epidemiological studies indicate that NAFLD fatal non-fatal CVD events. patients have higher arterial plaques stiffness, coronary calcification, endothelial dysfunction. Although genetic environmental factors strongly contribute pathogenesis, Mendelian randomization analysis indicated PNPLA3 variant leading may be causally associated risk. Among other variants NAFLD, TM6SF2 appears protective, whereas MBOAT7 favour venous thromboembolism.NAFLD correlated which ameliorated interventions. This surprising, since new criteria defining include abnormalities fuelling development serious adverse extrahepatic outcomes, for example CVD. The lack targeted pharmacological approach makes identification at (eg hypertension, obesity high levels C-reactive protein) major clinical interest.

Language: Английский

---

Chronic lead exposure induces fatty liver disease associated with the variations of gut microbiota

Ecotoxicology and Environmental Safety, Journal Year: 2022, Volume and Issue: 232, P. 113257 - 113257

Published: Jan. 29, 2022

Lead (Pb) has been suggested as an endocrine-disrupting chemical. However, few studies have investigated the association between chronic Pb exposure and fatty liver disease.We aimed to investigate of with disease whether variations gut microbiota involve in mechanism induced by exposure.We conducted a cross-sectional study 3066 rural participants East China. Blood lead level (BLL) was detected, abdominal ultrasonography used diagnose hepatic steatosis. Both definition non-alcoholic (NAFLD) metabolic dysfunction-associated (MAFLD) were used. Wistar rats randomly divided into two groups each group exposed 0 or 0.05% w/v through drinking water for 28 weeks. The relevant parameters lipid metabolism analyzed.In humans, after adjusting potential confounders, odds having NAFLD MAFLD significantly increased 54% 52% fourth BLL quartile (OR 1.54, 95% CI 1.24, 1.91 OR 1.52, 1.22, 1.89). In rats, visceral fat, steatosis, dysbiosis microbiota, including decrease richness, diversity, evenness phylogenetic diversity significant alternations composition, particularly, relative abundance Coprococcus Oscillospira at genus level.Chronic could induce disease, which may be associated microbiota.

Language: Английский

---